CDDO-Im

CAS No. 443104-02-7

CDDO-Im( RTA-403 | TP-235 | CDDO-Imidazolide )

Catalog No. M24402 CAS No. 443104-02-7

CDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 65 In Stock
10MG 102 In Stock
25MG 200 In Stock
50MG 320 In Stock
100MG 484 In Stock
500MG 1035 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDDO-Im
  • Note
    Research use only, not for human use.
  • Brief Description
    CDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
  • Description
    CDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
  • In Vitro
    CDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines (IC50 approximately 10-30 nM). In U937 leukemia cells, CDDO-Im also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36. Treatment with CDDO-Im elevates protein levels of Nrf2, a transcription factor previously shown to bind ARE sequences, and increases expression of a number of antioxidant and detoxification genes regulated by Nrf2. CDDO-Im is one of the most potent synthetic triterpenoids shown to induce growth inhibition and apoptosis in various human cancer cells, including multiple myeloma, lung, pancreas and breast cancer. CDDO-Im treatment markedly induces cell cycle arrest at G2/M-phase and apoptosis in the triple-negative breast cancer cell lines, SUM159 and MDA-MB-231. The CD24?/EpCAM+ cells in SUM159 tumorspheres are significantly inhibited by CDDO-Im treatment. CDDO-Im also significantly decreases sphere forming efficiency and tumorsphere size in both primary and secondary sphere cultures.
  • In Vivo
    CDDO-Im is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, CDDO-Im inhibits growth of B16 murine melanoma and L1210 murine leukemia cells in vivo. Injection of 10 nM (5.4 μg) of CDDO-Im almost completely blocks the ability of IFN-γ to induce iNOS, and treatment with as little as 1 nmol of CDDO-Im (0.54 μg) is partially effective.
  • Synonyms
    RTA-403 | TP-235 | CDDO-Imidazolide
  • Pathway
    Nuclear Receptor/Transcription Factor
  • Target
    Keap1-Nrf2
  • Recptor
    Nrf2|PPAR|PPARα|PPARγ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    443104-02-7
  • Formula Weight
    541.72
  • Molecular Formula
    C34H43N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:50 mg/mL (92.30 mM; Need ultrasonic);Water:Insoluble
  • SMILES
    C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)N6C=CN=C6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.
molnova catalog
related products
  • ML334

    ML334 (LH601A) is a transmembrane and potent NRF2 activator that inhibits Keap1-NRF2 protein interactions to ameliorate myocardial infarction-induced cardiac fibrosis by inhibiting cardiac fibroblast activation and proliferation.

  • VVD-130037

    VVD-130037 is a small molecule activator specifically targeting Kelch-like ECH-associated protein 1 (KEAP1) with potential antitumor activity.

  • Nrf2 activator-1

    Nrf2 activator-1 is a potent activator of NF-E2-related factor 2 (Nrf2) and can be used to study COPD and other respiratory diseases, including asthma, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and pulmonary fibrosis.